

Table 1 Graph summarizing current real-world data on safety and efficacy of emicizumab in children < 3 years of age with severe hemophilia A and inhibitor

Patient	Study/Authors (Reference#)	Age Emicizumab Initiated	ITI Before Emicizumab	ITI After Emicizumab	Emicizumab Indication	Emicizumab Dose and Frequency After Loading doses	CVC	Hemarthrosis or Spontaneous Bleed	Thrombosis or TMA
≤ 6 months of age									
#1	4	2 mo.	No	No	Intensive daily FVIII for ICH and CVC removal	1.5 mg/kg weekly	Yes	No*	No
#2	Our Study	6 mo.	No	No	Intensive daily FVIII for ICH and CVC avoidance	1.5 mg/kg weekly	No	No	No
>6 months-3 years of age									
#3	4	0.75 yr.	Yes	No	No data	1.5 mg/kg weekly	No	No	No
#4	4	0.75 yr.	No	No	No data	1.5 mg/kg weekly	No	No	No
#5	4	0.92 yr.	No	No	No data	1.5 mg/kg weekly	No	No	No
#6	4	1 yr.	No	No	FVIII allergy and recurrent hemarthrosis while on rFVIII prophylaxis	1.5 mg/kg weekly	No	No	No
#7	4	1.3 yr.	No	No	No data	1.5 mg/kg weekly	No	No	No
#8	4	1.5 yr.	Yes	No	Avoidance of CVC	1.5 mg/kg weekly	No	No	No
#9	4	2.3 yr.	No	No	No data	1.5 mg/kg weekly	No	No	No
#10	5	0.75 yr.	No	No	No data	No data	No	No	No
#11	5	1 yr.	No	No	No data	No data	No	No	No
#12	5	2.6 yr.	Yes	No	CVC removal	No data	Yes	No	No
#13	Our Study	1.6 yr.	Yes	Yes	Breakthrough bleeding on daily ITI	1.5 mg/kg weekly	Yes	No	No
#14	Our Study	2.3 yr.	No	No	Avoidance of CVC	1.5 mg/kg weekly	No	No	No

ITI, immune tolerance therapy; CVC, central venous catheter; TMA, thrombotic microangiopathy; mo., months; F, factor; ICH, intracranial hemorrhage; yr., years; r, recombinant; *post circumcision bleed